Naturalistic survey on nonsteroidal antiinflammatory treatment in patients with musculoskeletal pain - 01/01/03
Philippe
Goupille
a
,
Isabelle
Logeart
b
,
Bernard
Combe
c
*
*Corresponding author.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 7 |
| Iconographies | 4 |
| Vidéos | 0 |
| Autres | 0 |
Résumé |
Objective and methods. - To evaluate patients' opinions about the gastrointestinal safety and areas for improvement of conventional nonsteroidal antiinflammatory drug (NSAID) therapy for musculoskeletal pain, the Louis Harris Institute conducted a survey in 401 patients selected in France using a quota sampling method.
Results. - Three hundred and five patients (76%) described their pain as incapacitating. Nearly, one-third of the patients (125/401, 31%) reported gastrointestinal side effects, which prompted endoscopy in 24 (24/125, 20%) and gastroprotective drug treatment (usually by a proton pump inhibitor) in 100 (100/125, 82%). NSAID discontinuation or dosage reduction because of gastrointestinal side effects occurred in 55 patients (55/125, 45%), at the cost of symptom exacerbation, including worse pain, in over half the cases. Among the 401 patients, 304 (76%) wanted more effective NSAIDs and 174 (43%) wanted better gastrointestinal tolerability.
Conclusion. - Under everyday conditions, the use and effectiveness of conventional NSAID therapy are limited by gastrointestinal side effects. Furthermore, patients want NSAIDs with better risk/benefit ratios to control musculoskeletal pain.
Mots clés : Survey ; NSAIDs ; Musculoskeletal pain ; Gastrointestinal safety ; Coxibs.
Plan
Vol 70 - N° 3
P. 219-225 - juin 2003 Retour au numéro
Article précédent
- Insufficiency fracture. A survey of 60 cases and review of the literature
- Martin Soubrier, Jean-Jacques Dubost, Stephane Boisgard, Bernard Sauvezie, Pierre Gaillard, Jean Luc Michel, Jean-Michel Ristori
- Late-onset spondyloarthropathy mimicking reflex sympathetic dystrophy syndrome
- Jean-Jacques Dubost, Martin Soubrier, Jean-Michel Ristori, Christophe Guillemot, Jean-Louis Bussière, Bernard Sauvezie
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?